Tag:
John Lechleiter
Latest Headlines
Latest Headlines
Lilly invests £5.4M in R&D hub in U.K.
Eli Lilly has opened a new building at its Erl Wood R&D center in Surrey, U.K., to house early-stage research.
You can't cut your way to success, Lilly CEO declares
Lechleiter says the company has got to find new treatments and sell more drugs to overcome the revenue decline it will see from losing the patents on its two top sellers.
Lilly CEO avoids Pfizer-like cuts, focuses on pipeline
John Lechleiter has held firm to his position that cutting expenses alone isn't a solution to the challenges at his company; he thinks that the way forward resides in the pipeline.
Lilly gains FDA approval for its controversial brain plaque test
Late on Friday, Eli Lilly put out the word that the FDA had approved its brain dye--Amyvid--for use in ruling out Alzheimer's.
Lilly hunkers down for lean years with salary freeze
Eli Lilly ( $LLY ), languishing in the doldrums of its long-expected "Years YZ," has frozen the salaries of many of its staffers, including those of top management. As Pharmalot reports, the company
Is Lilly betting the farm on its high-stakes Alzheimer's gamble?
Now that the patent cliff has arrived right on time for Eli Lilly ( $LLY ), the big question this year is whether or not its massive gamble on the Alzheimer's drug solanezumab will pay off. That's
Lilly's losses put pressure on key Alzheimer's program
Eli Lilly ( $LLY ) saw its fourth-quarter profit slide 27% after the loss of its patent on Zyprexa last year hit sales of the schizophrenia drug harder than expected, Bloomberg reported. And the fresh
Lilly's Lechleiter sees pharma clouds abroad
Eli Lilly ( $LLY ) CEO John Lechleiter ( photo ) says price squeezes in Europe and Japan will be key challenges to his company's sales in 2012, one week after the company predicted a bigger-than-expected
Lilly surprises with lower-than-expected 2012 forecast
Eli Lilly ( $LLY ) has long been warning about a yearslong sales trough, and those years have officially arrived. But the company says it's now projecting a deeper-than-expected drop in profits for
Bleak forecast puts Eli Lilly's ambitious R&D game plan to the test
Eli Lilly ( $LLY ) stepped right up to the edge of the patent cliff this morning, looked down and predicted a $3 billion drop in Zyprexa sales as cheaper generics muscle into the market. The bleak
